Sylvain Malfroy1, Florent Wallet2, Delphine Maucort-Boulch3, Laurent Chardonnal2, Nicolas Sens2, Arnaud Friggeri2, Guillaume Passot4, Olivier Glehen4, Vincent Piriou2. 1. Anesthesiology and Critical Care Department, CHU Lyon Sud, Université Lyon 1, Pierre Benite, France. Electronic address: sylvain.malfroy@chu-lyon.fr. 2. Anesthesiology and Critical Care Department, CHU Lyon Sud, Université Lyon 1, Pierre Benite, France. 3. Biostatistic Unit, Hospices Civils de Lyon, F-69003, Lyon, France; CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, F-69100, Villeurbanne, France. 4. Department of Surgical Oncology, CHU Lyon Sud, Lyon 1 University, EMR 3738, Pierre Benite, France.
Abstract
BACKGROUND AND OBJECTIVES: For patients suffering from peritoneal carcinomatosis, cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the only curative option. We focused on severe complications in the postoperative course of HIPEC. METHODS: We studied perioperative data from patients who underwent HIPEC between January 2010 and August 2011. Our primary objective was to identify perioperative risk factors for ICU admission. Our secondary objective was to identify patient that may be re-admitted to the ICU thanks to a prognostic score. RESULTS: 122 patients underwent HIPEC. 32 presented severe adverse events (26.2%) and 7 died (5.7%). Reasons for ICU admission were septic shock in 28.1% of patients, hemorrhagic shock for 21.9%, hemodynamic instability for 15.6%, respiratory causes for 6.2% and post-operative acidosis for 6.2%. Vasopressors were required for 34% and 40.6% were mechanically ventilated. CONCLUSION: Peritoneal cancer index, diaphragmatic peritonectomy, the need of vasopressive therapy, total volume of fluid leakage collected in drains and total volume of fluid therapy administered at day 1 reported on ideal body weight were the 5 significant variables that we combined to build a morbidity prognostic score. One patient over 4 is likely to present severe complications. A predictive morbidity score provide informative data for clinicians.
BACKGROUND AND OBJECTIVES: For patients suffering from peritoneal carcinomatosis, cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the only curative option. We focused on severe complications in the postoperative course of HIPEC. METHODS: We studied perioperative data from patients who underwent HIPEC between January 2010 and August 2011. Our primary objective was to identify perioperative risk factors for ICU admission. Our secondary objective was to identify patient that may be re-admitted to the ICU thanks to a prognostic score. RESULTS: 122 patients underwent HIPEC. 32 presented severe adverse events (26.2%) and 7 died (5.7%). Reasons for ICU admission were septic shock in 28.1% of patients, hemorrhagic shock for 21.9%, hemodynamic instability for 15.6%, respiratory causes for 6.2% and post-operative acidosis for 6.2%. Vasopressors were required for 34% and 40.6% were mechanically ventilated. CONCLUSION: Peritoneal cancer index, diaphragmatic peritonectomy, the need of vasopressive therapy, total volume of fluid leakage collected in drains and total volume of fluid therapy administered at day 1 reported on ideal body weight were the 5 significant variables that we combined to build a morbidity prognostic score. One patient over 4 is likely to present severe complications. A predictive morbidity score provide informative data for clinicians.
Keywords:
Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Intensive care unit admission; Peritoneal surface malignancies; Severe complications
Authors: Carlos E Guerra-Londono; Pascal Owusu-Agyemang; German Corrales; Marina M Rofaeil; Lei Feng; Keith Fournier; Juan P Cata Journal: Ann Surg Oncol Date: 2021-10-26 Impact factor: 5.344
Authors: Piet de Witte; Christien A de Witt; Johan L van de Minkelis; Djamila Boerma; H Frank Solinger; C Erik Hack; Peter Bruins Journal: J Gastrointest Oncol Date: 2019-04
Authors: Sumit Kapoor; Adel Bassily-Marcus; Rafael Alba Yunen; Parissa Tabrizian; Sabrine Semoin; Joseph Blankush; Daniel Labow; John Oropello; Anthony Manasia; Roopa Kohli-Seth Journal: World J Crit Care Med Date: 2017-05-04
Authors: Ángela Bella; Leire Arrizabalaga; Claudia Augusta Di Trani; Assunta Cirella; Myriam Fernandez-Sendin; Celia Gomar; Joan Salvador Russo-Cabrera; Inmaculada Rodríguez; José González-Gomariz; Maite Alvarez; Álvaro Teijeira; José Medina-Echeverz; Maria Hinterberger; Hubertus Hochrein; Ignacio Melero; Pedro Berraondo; Fernando Aranda Journal: Oncoimmunology Date: 2022-07-13 Impact factor: 7.723
Authors: Lukas F Liesenfeld; Benedikt Wagner; H Christian Hillebrecht; Maik Brune; Christoph Eckert; Johannes Klose; Thomas Schmidt; Markus W Büchler; Martin Schneider Journal: Ann Surg Oncol Date: 2021-07-14 Impact factor: 5.344